Skip to search formSkip to main contentSkip to account menu

Vacc-4x

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

AIDS Vaccines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals
Objective: Therapeutic HIV-1 immunization followed by latency reversal has been suggested as a strategy to eradicate HIV-1. Here… 
2017
2017
Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.
Highly Cited
2016
Highly Cited
2016
Combined eff ect of Vacc-4 x , recombinant human granulocyte macrophage colony-stimulating factor vaccination , and romidepsin on the HIV-1 reservoir ( REDUC ) : a single-arm , phase 1 B / 2 A trial
Methods In this single-arm, phase 1B/2A trial, we recruited adults treated at the Department of Infectious Diseases, Aarhus… 
2016
2016
Expanding coverage of paediatric HIV testing.
2012
2012
Delayed‐type hypersensitivity responses to HIV Gag p24 relate to clinical outcome after peptide‐based therapeutic immunization for chronic HIV infection
Kran A‐MB, Sommerfelt MA, Baksaas I, Sørensen B, Kvale D. Delayed‐type hypersensitivity responses to HIV Gag p24 relate to… 
2010
2010
Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection.
Vacc-4x is being developed by Bionor Immuno AS as a therapeutic vaccine to be used in conjunction with antiretroviral therapies… 
2006
2006
Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells
Long-term HIV-specific immune responses and clinical outcomes were evaluated in HIV-infected patients previously immunized with… 
2005
2005
Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Highly Cited
2004
Highly Cited
2004
HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x)
Objective: The Vacc-4x immunotherapy candidate is composed of four modified peptides corresponding to conserved domains of the… 
2002
2002
Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
Highly active antiretroviral therapy (HAART) can effectively suppress HIV-1 replication but, as soon as the drugs are withdrawn… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)